correlation between blood levels of immune co-inhibitory molecules disease severity and treatment response in alopecia areata patients

Not Applicable

Conditions: Health Condition 1: L639- Alopecia areata, unspecified

Registration Number: CTRI/2021/03/032196

Lead Sponsor: Post Graduate Institute of Medical Education and Research Chandigarh

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: ot Yet Recruiting

Sex: Not specified

Target Recruitment: 0

Inclusion Criteria

Patients having a clinical diagnosis of patchy alopecia areata having developed two or more patches of active hair loss on scalp within past 3 months and having positive hair pull test at the time of presentation.

Hair pull test will be performed at the edge of the patch of alopecia areata. (A tuft of approximately 60 hair is grasped near the scalp with the thumb, index and middle finger of the examiner. A gentle but firm traction is applied and number of hair pulled out is analysed. A count of more than 10 % of grasped hair i.e., 6 strands of hair will be considered as positive hair pull test.

Exclusion Criteria

1.alopecia areata not involving the scalp at baseline

2.Alopecia secondary to other causes

3.Pregnancy/Lactation

4.Patients with severe hepatic, renal, or other systemic disorder

5.Pre-existing malignancy

6.Any other skin disease

7.Patients receiving topical or systemic therapy of any form for alopecia areata in past 4 weeks.

8.Patients younger than 18 or older than 60 years of age

Study & Design

Study Type: Observational

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1.Expression of mPD-1 in patients and controls <br/ ><br>2.Expression of mPDL-1 in patients and controls <br/ ><br>Timepoint: Expression of mPD-1, mPDL-1, sPD-1, sPDL-1, SALT score, clinical photography will be assessed at baseline.Patients will be followed up every 4 weeks, for 16 weeks. At each follow up, SALT score and clinical photography will be done

Secondary Outcome Measures

Name	Time	Method
1.Serum SPD-1 levels of patients, controls <br/ ><br>2.Serum levels of sPDL-1 levels of patients and controls <br/ ><br>3.SALT score <br/ ><br>4.Hair pull test <br/ ><br>5.Hull and Norris score <br/ ><br>Timepoint: Expression of mPD-1, mPDL-1, sPD-1, sPDL-1, SALT score, clinical photography will be assessed at baseline.Patients will be followed up every 4 weeks, for 16 weeks. At each follow up, SALT score and clinical photography will be done